Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. by Holman, Rury R et al.
                             Elsevier Editorial System(tm) for The Lancet 
Diabetes & Endocrinology 
                                  Manuscript Draft 
 
 
Manuscript Number: THELANCETDE-D-17-00578R1 
 
Title: Effects of Acarbose on Cardiovascular and Diabetes Outcomes in 
Patients with Coronary Heart Disease and Impaired Glucose Tolerance: A 
Randomised Controlled Trial  
 
Article Type: Article (Clinical Trials) 
 
Corresponding Author: Professor Rury R Holman,  
 
Corresponding Author's Institution: University of Oxford 
 
First Author: Rury R Holman 
 
Order of Authors: Rury R Holman; Ruth L Coleman; Juliana C Chan; Jean-
Louis Chiasson; Huimei Feng; Junbo Ge; Hertzel C Gerstein; Richard Gray; 
Yong Huo; Zhihui Lang; John J McMurray; Lars Rydén; Stefan  Schröder; 
Yihong Sun; Michael J Theodorakis; Michal Tendera; Lynne Tucker; Jaakko 
Tuomilehto; Yidong Wei; Wenying Yang; Duolao Wang; Dayi Hu; Changyu Pan 
 
Manuscript Region of Origin: UNITED KINGDOM 
 
Abstract: Background 
The impact of acarbose on cardiovascular outcomes in patients with 
coronary heart disease and impaired glucose tolerance is unknown.  
Methods 
Chinese patients with coronary heart disease and impaired glucose 
tolerance were randomly assigned to double-blind acarbose 50 mg three 
times daily or placebo, added to standard cardiovascular secondary 
prevention therapy. We hypothesised that acarbose would be superior to 
placebo for a composite outcome of cardiovascular death, nonfatal 
myocardial infarction, nonfatal stroke, hospitalisation for unstable 
angina or hospitalisation for heart failure. This study is completed and 
registered with ClinicalTrials.gov NCT00829660 and ISRCTN 91899513. 
Findings 
Of 6526 patients randomised, 6522 were followed for median 5·0 years. The 
primary composite outcome occurred in 470 patients in the acarbose group 
(14·4%; 3·33 per 100 person-years) and 479 in the placebo group (14·7%; 
3·41 per 100 person-years). Acarbose was not superior to placebo for the 
primary outcome (hazard ratio 0·98; 95% Confidence Interval [CI] 0·86 to 
1·11; P=0·73), with no significant subgroup interactions. No significant 
differences were seen between acarbose and placebo groups for the 
secondary composite outcome (cardiovascular death, nonfatal myocardial 
infarction, nonfatal stroke), death from any cause, cardiovascular death, 
fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, 
hospitalisation for unstable angina, or hospitalisation for heart 
failure. Diabetes developed less frequently in the acarbose group (N=436, 
13·3%; 3·17 per 100 person-years) compared with the placebo group (N=513, 
15·8%; 3·84 per 100 person-years) (rate ratio 0·82; 95% CI 0·71 to 0·94; 
P=0·005). Apart from gastrointestinal disorders, adverse event rates did 
not differ between groups. 
Interpretation 
In Chinese patients with coronary heart disease and impaired glucose 
tolerance, acarbose did not reduce the risk of major adverse 
cardiovascular events but did reduce the incidence of diabetes. 
Funding 
Bayer AG. 
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Background 1 
The impact of acarbose on cardiovascular outcomes in patients with coronary heart disease and 2 
impaired glucose tolerance is unknown.  3 
Methods 4 
Chinese patients with coronary heart disease and impaired glucose tolerance were randomised to 5 
double-blind acarbose 50 mg three times daily or placebo, added to standardised cardiovascular 6 
secondary prevention therapy. Acarbose was hypothesised to be superior to placebo for a 7 
composite outcome of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, 8 
hospitalisation for unstable angina or hospitalisation for heart failure. The completed study is 9 
registered with ClinicalTrials.gov NCT00829660 and ISRCTN 91899513. 10 
Findings 11 
Of 6526 patients randomised, 6522 were followed for median 5·0 years. The primary composite 12 
outcome occurred in 470 acarbose group participants (14·4%; 3·33 per 100 person-years) and in 13 
479 placebo group participants (14·7%; 3·41 per 100 person-years). Acarbose was not superior to 14 
placebo for the primary outcome (hazard ratio 0·98; 95% Confidence Interval [CI] 0·86 to 1·11; 15 
P=0·73), with no significant subgroup interactions. No significant differences were seen between 16 
treatment groups for the secondary composite outcome (cardiovascular death, nonfatal myocardial 17 
infarction, nonfatal stroke), death from any cause, cardiovascular death, fatal or nonfatal 18 
myocardial infarction, fatal or nonfatal stroke, hospitalisation for unstable angina, or hospitalisation 19 
for heart failure. Diabetes developed less frequently in the acarbose group (N=436, 13·3%; 3·17 20 
per 100 person-years) compared with the placebo group (N=513, 15·8%; 3·84 per 100 person-21 
years) (rate ratio 0·82; 95% CI 0·71 to 0·94; P=0·005). Gastrointestinal disorders were numerically 22 
more frequent with acarbose but adverse event rates did not differ significantly between groups. 23 
Interpretation 24 
In Chinese patients with coronary heart disease and impaired glucose tolerance, acarbose did not 25 
reduce the risk of major adverse cardiovascular events but did reduce the incidence of diabetes. 26 
Funding 27 
Bayer AG.   28 
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Introduction 1 
People with coronary heart disease and impaired glucose tolerance are at increased risk of future 2 
cardiovascular events1,2,3 and developing type 2 diabetes.4 In 2006, the prevalence of impaired 3 
glucose regulation in Chinese adults hospitalised for coronary artery disease was 37·3%.5  4 
After the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) reported that 5 
acarbose, an alpha-glucosidase inhibitor, reduced the incidence of type 2 diabetes by 25% in 6 
people with impaired glucose tolerance,6 it was approved for treating this condition in China and 7 
elsewhere. A subsequent pre-specified STOP-NIDDM secondary analysis suggested a decreased 8 
risk of a cardiovascular composite outcome7, although only 47 participants experienced such an 9 
event in the low cardiovascular risk population enrolled. Acarbose has also been shown to slow 10 
progression of carotid artery intima-media thickness in people with impaired glucose tolerance.8 A 11 
meta-analysis of seven trials showed that acarbose reduced cardiovascular events by one third in 12 
patients with type 2 diabetes, although none were specifically designed to test this hypothesis.9 13 
These and other data support a possible cardiovascular disease prevention role for acarbose.10 14 
The Acarbose Cardiovascular Evaluation (ACE) trial examined whether acarbose could reduce 15 
cardiovascular events in Chinese patients with established coronary heart disease and impaired 16 
glucose tolerance, and whether the incidence of type 2 diabetes could be reduced.11,12 17 
 18 
Methods 19 
Study Design 20 
This randomised, double-blind, placebo-controlled, event-driven, Phase IV superiority trial was 21 
conducted at 176 sites in China.11,12 Designed and overseen by a Steering Committee of 14 22 
academic investigators and two Bayer employees, it was run independently by the University of 23 
Oxford Diabetes Trials Unit,13 with the University of Oxford as the Sponsor. The protocol (available 24 
on-line at http://www.dtu.ox.ac.uk/ACE/protocol.php) was approved by the University of Oxford 25 
Tropical Research Ethics Committee, and by central or local ethics committees (as appropriate) at 26 
participating sites. Participants provided written informed consent. The Appendix contains 27 
organisational details and a list of participating sites and investigators. An independent Data and 28 
Safety Monitoring Board performed on-going safety surveillance with full access to unblinded data.  29 
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 1 
Participants 2 
Selection criteria and baseline characteristics of participants have been published.11,12,14 These are 3 
listed in the Appendix, but briefly those eligible were ≥50 years old with established coronary heart 4 
disease (defined as prior myocardial infarction, unstable angina or current stable angina), and 5 
impaired glucose tolerance (confirmed by a 75g oral glucose tolerance test) who had taken ≥80% 6 
of single-blind placebo study medication during a four-week run-in period. During the run-in period 7 
investigators were required to provide all participants with appropriate lifestyle advice with respect 8 
to diet, exercise and smoking. Also, existing cardiovascular therapy was optimised (if required) to 9 
be consistent with internationally accepted treatment guidelines, including antiplatelet agents, 10 
statins, beta-blockers, renin-angiotensin-aldosterone inhibitors, and blood pressure lowering 11 
therapy as appropriate.  12 
 13 
Randomisation and Masking 14 
Participants were randomised 1:1 by a centralised computer system to acarbose 50mg three times 15 
daily with meals or to matching placebo, blocked within site. The 50mg acarbose dose was chosen 16 
because that was the usual dose used in China for people with impaired glucose tolerance and 17 
because of the high study medication discontinuation rate seen in STOP-NIDDM with a dose of 18 
100mg three times daily (31% acarbose versus 19% placebo during median 3·3 years’ follow-up, 19 
with 48% of these participants discontinuing in the first year), mainly secondary to gastrointestinal 20 
side effects which are dose dependent. The randomisation sequence (coded as “A” or “B”) was 21 
generated by a Diabetes Trials Unit statistician unconnected to the trial and uploaded to the 22 
electronic Rave Trial Management System (rTMS, Medidata Rave, New York). Acarbose and 23 
matching placebo tablets were provided by Bayer packaged in four month quantities, each packet 24 
being labelled with a unique code. These codes were also uploaded to the rTMS with their 25 
corresponding “A” or “B” categorisation which was not visible to study staff. At the time of 26 
randomisation, and at subsequent visits, investigators were instructed by the rTMS which study 27 
medication packet should be given to each participant. They were required to enter two letters 28 
printed alongside the unique code on the packet label so that the rTMS could confirm the correct 29 
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study medication had been dispensed. Up until database lock, the assignation of “A” or “B” to 1 
active or placebo was known only to the Bayer study medication packaging group and the Data 2 
Safety and Monitoring Board. 3 
 4 
Procedures 5 
Follow-up visits were performed at one, two, four, and then every four months to provide study 6 
medication, measure fasting plasma glucose, blood pressure and weight, and to ascertain clinical 7 
outcomes, monitor study medication adherence and collect serious adverse events that were not 8 
prespecified as study endpoints. At annual visits, oral glucose tolerance tests were conducted, 9 
glycated haemoglobin (HbA1c) measured and serum creatinine measurements performed with 10 
estimated glomerular filtration rate (eGFR) calculated using the Modification of Diet in Renal 11 
Disease study equation, adapted for a Chinese population.15 Whenever a four-monthly fasting 12 
plasma glucose value was ≥7·0 mmol/L an additional oral glucose tolerance test was scheduled to 13 
confirm the diagnosis of diabetes. Those who developed diabetes remained on blinded study 14 
medication with the addition of metformin or other glucose-lowering agents (except 15 
alphaglucosidase inhibitors), if required to maintain acceptable glycaemic control. 16 
Non-serious adverse events were not collected unless related to the cessation or change in dose 17 
of study medication, as acarbose is licensed in China for treatment of impaired glucose tolerance. 18 
Adverse events were coded using the Medical Dictionary for Regulatory Activities Dictionary 19 
version 14·1.   20 
 21 
Outcomes 22 
During the trial, slow recruitment and lower than anticipated event rates required the Steering 23 
Committee to amend the protocol ahead of database lock.14 This was done in a blinded manner 24 
with no involvement of the Data Safety and Monitoring Board. The primary composite 25 
cardiovascular outcome, a 3-point major cardiovascular adverse event [MACE] outcome (first 26 
occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) was 27 
expanded to a 5-point MACE to include hospitalisation for unstable angina and hospitalisation for 28 
heart failure. Heart failure was included in the composite as a cardiovascular outcome that can no 29 
 
Page 7 of 29 
longer be ignored,16 and given evidence that glucagon-like peptide-1, which is elevated by 1 
acarbose,17 can improve left ventricular function.18 The 3-point MACE became a secondary 2 
outcome.14 In addition, the sample size was reduced from 7500 to 6500, and the power to detect a 3 
20% reduction in the primary composite outcome was reduced from 90% to 85%, requiring ≥728 4 
rather than ≥904 participants to have had a confirmed event. 5 
The other secondary outcomes were all-cause death; cardiovascular death; nonfatal myocardial 6 
infarction; nonfatal stroke; hospitalisation for unstable angina; hospitalisation for heart failure; as 7 
well as the proportion of participants developing diabetes confirmed by two successive diagnostic 8 
plasma glucose values (defined as fasting plasma glucose ≥126 mg/dl [≥7·0 mmol/L] and/or two-9 
hour plasma glucose ≥200 mg/dl [≥11·1 mmol/L]), with no intervening non-diagnostic values, or 10 
diagnosed outside of the study, and the proportion of participants developing impaired renal 11 
function (defined as ≥1 of eGFR <30 ml/min/1·73m2, doubling of baseline serum creatinine level, or 12 
halving of baseline eGFR). To avoid confounding by competing mortality risks, we have chosen to 13 
report fatal or nonfatal myocardial infarction and fatal or nonfatal stroke as post hoc secondary 14 
endpoints, rather than nonfatal myocardial infarction and nonfatal stroke. The final secondary 15 
outcome is resource use, costs and cost effectiveness. These health economic outcomes are 16 
beyond the scope of this manuscript and will be reported elsewhere. 17 
Participants were followed until study closeout whenever possible, regardless of whether they were 18 
taking study medication.  Vital status ascertainment was completed by the investigator at study 19 
closeout visits, and for those lost to follow-up or who had withdrawn consent by searches 20 
conducted using local or national electronic health records, death registries, or other publicly 21 
available sources (where permitted by local ethics approvals). 22 
Event Adjudication 23 
Potential cardiovascular end points were reviewed and adjudicated in a blinded fashion by an 24 
independent Cardiovascular Endpoint Adjudication Committee. Each event was reviewed by two 25 
adjudicators, and was referred to the full committee if their categorisation of the event differed. 26 
Where it was not possible to fully adjudicate an event due to lack of source data (for example 27 
absence of cardiac biomarkers in a suspected MI) the committee had the option to classify the 28 
event as “probable” rather than “definite”. During the study the UK-based Cardiovascular Endpoint 29 
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Adjudication Committee was replaced by a China-based Cardiovascular Endpoint Adjudication 1 
Committee when it became apparent that supporting documents translated from Mandarin to 2 
English did not fully capture the information needed for a robust adjudication process. 3 
An independent Diabetes Endpoint Adjudication Committee reviewed cases in a blinded fashion 4 
where diabetes was diagnosed, or participants are commenced on glucose lowering therapy, 5 
outside of the trial to decide if a diagnosis of diabetes was warranted. 6 
 7 
Statistical Methods 8 
We estimated that ≥728 participants with a confirmed composite primary outcome were required 9 
for the trial to have at least 85% power to detect a 20% risk reduction for acarbose, compared with 10 
placebo (two-sided alpha=0·05). For time-to event analyses, Kaplan-Meier curves were plotted and 11 
compared using log-rank tests according to randomised assignment.  A Cox regression model with 12 
treatment arm as a predictor was used to derive the hazard ratio and 95% confidence interval (CI). 13 
As development of diabetes and impaired kidney function events are interval censored, they were 14 
analysed using discrete time proportional odds regression models. The analysis of the primary 15 
composite outcome was based only on events that were adjudicated as definite or probable, with a 16 
sensitivity analysis limited only to definite events. Sensitivity analyses for key endpoints were also 17 
performed in the on-treatment population, a subset of the intent-to-treat population that censored 18 
participants when they discontinued study medication.  19 
Safety analyses were conducted in the safety population, a subset of the intent-to-treat population 20 
who received at least one study medication dose. Possible subgroup interactions for the primary 21 
composite outcome with sex, Chinese region, coronary heart disease inclusion criteria, prior heart 22 
failure, age at randomisation, as well as baseline HbA1c, fasting plasma glucose, two-hour plasma 23 
glucose, systolic blood pressure, body mass index and eGFR were explored in stratified log-rank 24 
analyses. Differences in biochemical and clinical characteristics over time were analysed using a 25 
linear mixed regression model. 26 
Continuous measures are summarised using descriptive statistics, mean, standard deviation, 27 
median and interquartile range as appropriate. For categorical variables, counts and percentage 28 
per treatment group are presented. All analyses were performed on the intention-to-treat (ITT) 29 
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population unless specified otherwise, with two-sided tests at the 0·05 level of significance using 1 
SAS software, version 9·2 or higher (SAS Institute). Interaction P values were not adjusted for 2 
multiple testing. 3 
 4 
Role of the Funding Source 5 
This academically-led study was funded by Bayer but designed by the Steering Committee (two 6 
members of which were Bayer employees). It was sponsored by the University of Oxford with the 7 
funder having no role in data collection, analysis, interpretation of the data, or writing of this report. 8 
All analyses were performed independently by the Diabetes Trials Unit according to the 9 
prespecified statistical analysis plan, and verified by an independent statistician (DW). RRH, RLC 10 
and DW had full access to the raw data. The corresponding author had full access to all of the data 11 
and the final responsibility to submit for publication. 12 
 13 
Results 14 
Study Participants 15 
Of 6526 patients randomised between March 20th 2009 and October 23rd 2015, 6522 were 16 
included in the intent-to-treat population as written consent for four patients could not be located 17 
(N=3272 for acarbose, N=3250 for placebo). Planned closeout of participant follow-up was from 1 18 
December 2016 to 18 April 2017. Vital status was ascertained for 94·4% of participants (Figure 1).   19 
Median follow up was 5·0 years (interquartile range [IQR] 3·4 to 6·0, maximum 7·9 years) in the 20 
acarbose group and 5·0 years (IQR 3·4 to 6·0, maximum 7·7 years) in the placebo group. The 21 
percentage of observed versus expected participant-years of follow-up for the primary composite 22 
outcome was 96·7% and 96·6% respectively. The mean percentage of time that participants 23 
received study drug was 77·5% and 76·4%, respectively, with premature study drug 24 
discontinuation primarily a participant decision (Appendix Figure S2). Overall, 29·8% and 31·4% 25 
respectively permanently discontinued study medication before completing the study with median 26 
treatment durations of 3·0 (1·3 to 5·0) and 3·0 (1·1 to 4·9) years. 27 
Baseline characteristics and use of cardiovascular medications did not differ between treatment 28 
groups (Table 1). All participants had prior coronary heart disease, categorised overall as 29 
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myocardial infarction (2712 of 6522, 41·6%), unstable angina (2715 of 6522, 41·7%) or stable 1 
angina (1417 of 6522, 21·7%) (not mutually exclusive). They were predominately male (4760 of 2 
6522, 73·0%), of Han ethnicity (6327 of 6522, 97·0%), with mean (standard deviation [SD]) age 3 
64·2 (8·1) years and body mass index 25·4 (3·1) kg/m2. Their cardiovascular risk factors were well 4 
managed, with mean systolic blood pressure 130 (14) mmHg (73% of participants <140 mmHg), 5 
LDL-cholesterol 87 (31) mg/dl (2·3 (0·8) mmol/L), eGFR 91 (43) ml/min/1·73m2 (6084 of 6522, 6 
92·6% of participants ≥60 ml/min/1·73m2), and 5697 of 6522 (87·3%) were non- or ex-smokers. 7 
Atrial fibrillation and prior heart failure were reported by the investigator in 274 of 6522 (4·2%) and 8 
262 of 6522 (4·0%) of participants respectively.  9 
 10 
Risk factor changes over time 11 
At one year, mean (SD) HbA1c was lower in the acarbose group compared with the placebo group 12 
(5·88 (0·65) versus 5·94 (0·65) %, P<0·0001), as were the 2-hour plasma glucose (8·4 (2·4) 13 
versus 8·7 (2·6) mmol/L, P<0·0001), triglycerides (1·49 (1·00) versus 1·62 (1·06) mmol/L, 14 
P<0·0001) and body weight (69·9 (10·9) versus 70·8 (11·0) kg, P<0·0001). These values 15 
remained lower in the acarbose group, compared with the placebo group, during the study with 16 
overall least-squares mean differences of −0·07% (95% confidence interval [CI] −0·04 to −0·10), 17 
−0·24% (95% CI −0·16 to −0·32), −0·09% (95% CI −0·07 to −0·12), and −0·64% (95% CI −0·53 to 18 
−0·75) respectively (Appendix Figure S1).  19 
At one year, no significant differences were seen between treatment groups for systolic blood 20 
pressure (130·3 (15·4) versus 130·4 (14.9) mmHg, P=0·53), diastolic blood pressure (78·2 (9·5) 21 
versus 78·5 (9·6) mmHg, P=0·93) or LDL-cholesterol (2·4 (0·9) versus 2·4 (0·9) mmol/L, P=0·37). 22 
During the study, overall least-squares mean differences showed lower LDL-cholesterol (–0·03 23 
mmol/L, 95% CI –0·05 to –0·01) and diastolic blood pressure (–0·32 mmHg, 95%CI –0·57 to –24 
0·07) but not systolic blood pressure (–0·27 mmHg, 95%CI –0·67 to 0·13) in the acarbose group 25 
compared with the placebo group. 26 
 27 
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Outcomes 1 
The primary outcome occurred in 470 of 3272 participants in the acarbose group (14·4%; 3·33 per 2 
100 person-years) and 479 of 3250 in the placebo group (14·7%; 3·41 per 100 person-years) 3 
(hazard ratio 0·98; 95% CI 0·8 to 1·11; P=0·73) (Table 2, Figure 2). The results did not differ when 4 
primary outcomes adjudicated as probable (19 acarbose, 15 placebo) were excluded (hazard ratio 5 
0·97, 95% CI 0·85 to 1·10, P=0·61), and the on-treatment analysis was similar (hazard ratio 1·07, 6 
95% CI 0·92 to 1·24, P=0·41). Hazard rates for the components of the primary composite outcome 7 
did not differ by treatment group (Appendix Figure S3) and no significant interactions were seen in 8 
the prespecified subgroup analyses (Appendix Figure S4).  9 
No statistically significant differences were seen between the acarbose and placebo groups for the 10 
3-point MACE outcome (hazard ratio 0·95, 95% CI 0·81 to 1·11, P=0·51), death from any cause, 11 
cardiovascular death, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalisation 12 
for unstable angina, or hospitalisation for heart failure (Table 2).  13 
Incident diabetes was lower in the acarbose group (N=436 of 3272, 13·3%; 3·17 per 100 person-14 
years) compared with the placebo group (N=513 of 3250, 15·8%; 3·84 per 100 person-years) (rate 15 
ratio 0·82; 95% CI 0·71 to 0·94; p=0·005) during median 4·4 years’ follow-up. Incident impaired 16 
kidney function did not differ between acarbose (N=41 of 3272, 1·3%, 0·33 per 100 person-years) 17 
and placebo (N=50 of 3250, 1·5%, 0·41 per 100 person-years) groups (rate ratio 0·81, 95% CI 18 
0·54–1·23, P=0·33). 19 
 20 
Safety outcomes 21 
The number of participants reporting mild and severe hypoglycaemic episodes did not differ 22 
between acarbose and placebo groups (719 of 3272 [22·0%] versus 664 of 3250 [20·4%], and 65 23 
of 3272 [2·0%] versus 63 of 3250 [1·9%] respectively). There were no clinically relevant 24 
differences in the incidence of events of clinical interest, serious adverse events or adverse events 25 
(Table 3), although bleeding events were more common with acarbose in participants whilst taking 26 
dual antiplatelet therapy (Appendix Table S1). Gastrointestinal disorders were numerically more 27 
frequent in the acarbose group compared with the placebo group for serious adverse events (92 of 28 
3272 [2·8%] versus 65 of 3250 [2·0%] respectively, P=0·057) and adverse events associated with 29 
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drug discontinuation or dose changes (252 of 3272 [7·7%] versus 179 of 3272 [5·5%] respectively, 1 
P=0·19). Neither non-cardiovascular death rates (71 of 3272 [2.2%] versus 56 of 3250 [1.7%], 2 
P=0·19) nor the incidence of cancer deaths (10 of 3272 [0.3%] versus 12 of 3250 [0.4%], P=0·08) 3 
differed between groups.  4 
 5 
Discussion 6 
Among Chinese patients with coronary heart disease and impaired glucose tolerance, addition of 7 
acarbose did not lower the rate of the primary composite outcome of cardiovascular death, non-8 
fatal myocardial infarction, non-fatal stroke, hospitalisation for unstable angina or hospitalisation for 9 
heart failure, compared with placebo. No statistically significant impact was seen with acarbose on 10 
the risk of all-cause death, 3-point MACE, or its individual components. Acarbose, however, 11 
reduced the risk of incident diabetes by 18% compared with placebo, with the number-needed-to-12 
treat to prevent one case of diabetes developing over 5 years being 41. There is no reason to 13 
believe that these findings cannot be extrapolated to equivalent but non-Chinese populations. 14 
Acarbose was reported to reduce cardiovascular events in a secondary analysis of the STOP-15 
NIDDM trial,7 but with only 47 participants having the outcome in question this could be a chance 16 
finding.19 The lack of any substantial benefit on cardiovascular events in ACE compared with 17 
STOP-NIDDM might reflect the lower dose of acarbose used (50 versus 100 mg three times daily), 18 
the younger population (54·5 versus 64·3 years), the different ethnic group, or the less-stringent 19 
cardiovascular risk targets in the 1990s.  Few large-scale studies have examined the impact of 20 
antihyperglycaemic agents targeting postprandial glucose excursions, with none showing 21 
cardiovascular benefit. The UK Prospective Diabetes Study randomised 1946 people with type 2 22 
diabetes double-blind to the addition of acarbose 100 mg three times daily or placebo for three 23 
years.20 Those allocated to acarbose had lower mean HbA1c values but no difference in “any 24 
diabetes-related end point” (hazard ratio 1·00, 95% CI 0·81 to 1·23) or microvascular disease 25 
(hazard ratio 0·91, 95% CI 0·61 to 1·35). The Assessment of an Alpha-Glucosidase Inhibitor to 26 
Block Cardiac Events in Patients With Myocardial Infarction and IGT (ABC) study with voglibose 27 
was terminated early as an interim analysis of the first 870 participants suggested a low probability 28 
of a positive outcome.21 Nateglinide, a rapid-acting insulin secretagogue which reduces 29 
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postprandial hyperglycemia by increasing circulating insulin levels, was evaluated in the 1 
Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) 2 
trial.22 In 9309 patients at high cardiovascular disease risk and with impaired glucose tolerance 3 
followed for median 5·0 years, nateglinide 120 mg once daily showed no effect on the risk of 4 
cardiovascular events and a 7% significant increased risk for new-onset diabetes.  5 
Whilst no direct effect of acarbose was seen on cardiovascular outcomes in our trial, a possible 6 
indirect effect should not be dismissed. Development of diabetes doubles the risk for major 7 
adverse cardiovascular events23 and it may be that in the longer term acarbose, by delaying or 8 
preventing diabetes in a people with coronary heart disease, could reduce their cardiovascular risk. 9 
Such a link was reported during the long-term passive follow-up of participants in the Da Qing 10 
diabetes prevention trial where individuals allocated to lifestyle modification who developed 11 
diabetes at a slower rate had a lower 23-year mortality rate than those allocated to the control 12 
group.24 13 
The 18% statistically significant lower risk of incident diabetes seen in the ACE trial high risk 14 
cardiovascular population was less than the 25% reduction observed over mean 3·3 years in the 15 
STOP-NIDDM low cardiovascular risk population (4·8% with a prior cardiovascular event).7 16 
Notably, STOP-NIDDM subjects were required to have a fasting plasma glucose concentration of 17 
5·6–7·7 mmol/L in addition to impaired glucose tolerance, increasing their risk of progression to 18 
diabetes 3·4 times more than having impaired fasting glucose alone.25 19 
ACE study strengths include the long follow-up period, accumulation of sufficient participants with 20 
a primary composite outcome to provide 90% power, the fact that they were well-treated with 21 
respect to classical cardiovascular risk factors, independent adjudication of all outcomes, and high 22 
ascertainment of vital status.  23 
Study limitations include the decline in study medication adherence over time reducing the 24 
possible impact of acarbose (although adherence did not differ between treatment groups), and the 25 
addition of hospitalisation for unstable angina and hospitalisation for heart failure components to 26 
the primary composite outcome which could mask more definitive cardiovascular events.26  27 
In Chinese patients with impaired glucose tolerance and coronary heart disease, acarbose did not 28 
reduce the risk of major cardiovascular events but did reduce the risk of new-onset diabetes.  29 
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Research in Context: 24 
Evidence before this study 25 
The Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) demonstrated that 26 
acarbose, an alphaglucosidase inhibitor, decreased the incidence or diabetes in a population with 27 
impaired glucose tolerance and at low cardiovascular risk. A pre-specified analysis of this study 28 
suggested a decreased risk of a cardiovascular composite outcome, but only 47 participants in 29 
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total experienced such an event. A meta-analysis of seven short term trials showed that acarbose 1 
reduced cardiovascular events by one third in patients with type 2 diabetes, although none were 2 
specifically designed to test this hypothesis. A Japanese trial, the Assessment of an Alpha-3 
Glucosidase Inhibitor to Block Cardiac Events in Patients With Myocardial Infarction and IGT 4 
(ABC), using another alphaglucosidase inhibitor (voglibose) was discontinued for futility. The only 5 
large-scale trial to date that has examined the cardiovascular impact of targeting postprandial 6 
glucose excursions with an antihyperglycaemic agent in a population at high cardiovascular risk 7 
and with impaired glucose tolerance was the Nateglinide And Valsartan in Impaired Glucose 8 
Tolerance Outcomes Research (NAVIGATOR) trial. This showed no effect on the risk of 9 
cardiovascular events and an increased risk for new-onset diabetes. 10 
Added value of this study 11 
This trial did not confirm the earlier STOP-NIDDM trial suggestion that acarbose might reduce 12 
cardiovascular risk in people with impaired glucose tolerance. It did, however, extend the known 13 
utility and safety of acarbose for delaying the onset of diabetes to a population with both coronary 14 
heart disease and impaired glucose tolerance. 15 
Implications of all the available evidence 16 
On the basis of the data from this trial and the NAVIGATOR study it would appear that, despite the 17 
strong epidemiological data linking postprandial hyperglycaemia to increased cardiovascular risk, 18 
directly targeting postprandial hyperglycaemia does not directly reduce the risk of cardiovascular 19 
events in populations at high cardiovascular risk and with impaired glucose tolerance. The reduced 20 
incidence of diabetes seen with acarbose in the ACE trial may, however, help reduce 21 
cardiovascular risk in the longer term by delaying the onset of diabetes in the high-risk population 22 
studied. 23 
  24 
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Figure Legends 
 
Figure 1. Enrollment, Follow-up, and Vital Status 
 
Figure 2. Rates of the primary cardiovascular outcome (composite of cardiovascular death, 
nonfatal myocardial infarction, nonfatal stroke, hospitalisation for unstable angina or 
hospitalisation for heart failure) (Panel A), the secondary cardiovascular outcome (composite 
of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) (Panel B), 
cardiovascular death (Panel C), and new-onset diabetes (Panel D) in the acarbose and 
placebo groups.  
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Table 1. Baseline Characteristics of the Trial Participants, According to Assigned Study Treatment 
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 Acarbose 
(N=3272) 
Placebo 
(N=3250) 
All participants 
(N=6522) 
Patient Demographics    
Age (years) 64.4 (8.2) 64.3 (8.0) 64.3 (8.1) 
 <65 1794 (54.8%) 1823 (56.1%) 3617 (55.5%) 
 ≥65 1478 (45.2%) 1427 (43.9%) 2905 (44.5%) 
Sex    
 Male 2395 (73.2%) 2365 (72.8%) 4760 (73.0%) 
 Female 877 (26.8%) 885 (27.2%) 1762 (27.0%) 
Race    
 Han 3183 (97.3%) 3144 (96.7%) 6327 (97.0%) 
 Other 89 (2.7%) 106 (3.3%) 195 (3.0%) 
Region    
 Beijing and Tianjin 515 (15.7%) 519 (16.0%) 1034 (15.9%) 
 Central 474 (14.5%) 471 (14.5%) 945 (14.5%) 
 South and Southwest 654 (20.0%) 634 (19.5%) 1288 (19.8%) 
 West and East 1125 (34.4%) 1124 (34.6%) 2249 (34.5%) 
 Northeast 485 (14.8%) 483 (14.9%) 968 (14.8%) 
 Hong Kong 18 (0.6%) 17 (0.5%) 35 (0.5%) 
Clinical Characteristics    
Weight (kg) 70.1 (10.7) 70.3 (11.0) 70.2 (10.8) 
Height (m) 1.66 (7.5) 1.66 (7.7) 1.66 (7.6) 
Body mass index (kg/m
2
) 25.3 (3.1) 25.5 (3.1) 25.4 (3.1) 
 <25 1543 (47.2%) 1473 (45.4%) 3016 (46.1%) 
 25-30 1514(46.3%) 1517 (46.7%) 3031 (46.3%) 
 ≥30 211 (6.5%) 257 (7.9%) 468 (7.2%) 
Waist circumference (cm) 91.0 (8.8) 91.5 (8.9) 91.2 (8.9) 
Systolic blood pressure (mmHg) 130 (14.2) 129 (14.1) 130 (14.2) 
Systolic blood pressure <140 mmHg 2399 (73.3%) 2344 (72.1%) 4743 (72.7%) 
Diastolic blood pressure (mmHg) 78 (9.2) 78 (9.2) 78 (9.2) 
Smoking    
 Never 1321 (40.4%) 1312 (40.6%) 2640 (40.5%) 
 Ex 1551 (47.4%) 1506 (46.3%) 3057 (46.9%) 
 Current 398 (12.2%) 425 (13.1%) 823 (12.6%) 
Consuming alcohol    
 Yes 309 (9.4%) 299 (9.2%) 608 (9.3%) 
 No 2961 (90.6%) 2951 (90.8%) 5912 (90.7%) 
Biochemical Characteristics    
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Fasting plasma glucose (mmol/l) 5.5 (0.86) 5.5 (0.78) 5.5 (0.82) 
Two-hour plasma glucose (mmol/l) 9.3 (1.1) 9.3 (1.1) 9.3 (1.1) 
HbA1c    
 (mmol/mol) 41 (8) 41 (7) 41 (7.8) 
 (%) 5.9 (0.8) 5.9 (0.7) 5.9 (0.7) 
Haemoglobin (g/L) 141 (15) 141 (15) 141 (15) 
Mean red cell corpuscular volume (fL) 91 (5.5) 92 (5.6) 92 (5.5) 
White blood cell count (x10
9/l
) 6.3 (1.6) 6.4 (1.7) 6.4 (1.7) 
Platelet count (x10
9/l
) 200 (57) 200 (57) 200 (57) 
Haematocrit  0.42 (0.05) 0.42 (0.04) 0.42 (0.04) 
Plasma alanine aminotransferase (U/L) 25.9 (14.6) 25.9 (15.2) 25.9 (14.9) 
Plasma creatinine (μmol/L) 79 (19) 79 (20) 79 (20) 
eGFR (ml/min/1.73m
2
) 88 (75 - 103) 89 (75 - 103) 88 (75 - 103) 
 <60 ml/min/1.73m
2
 234 (7.2%) 249 (7.7%) 438 (7.4%) 
Total cholesterol (mmol/L) 4.1 (1.1) 4.1 (1.0) 4.1 (1.0) 
HDL-cholesterol (mmol/L) 1.18 (0.31) 1.18 (0.30) 1.18 (0.30) 
LDL-cholesterol (mmol/L) 2.27 (0.82) 2.25 (0.78) 2.26 (0.80) 
Triglycerides (mmol/L) 1.37 (1.00 to 1.91) 1.36 (0.99 to 1.91) 1.36 (1.00 to 1.91) 
Coronary Heart Disease Inclusion Criteria    
Previous myocardial infarction 1350 (41.3%) 1362 (41.9%) 2712 (41.6%) 
Previous unstable angina 1352 (41.3%) 1363 (42.0%) 2715 (41.7%) 
Current stable angina 727 (22.2%) 690 (21.2%) 1417 (21.7%) 
Cardiovascular therapies    
Lipid-lowering therapy    
Statins 3038 (93.0%) 3028 (93.3%) 6066 (93.2%) 
Fibrate 35 (1.1%) 32 (1.0%) 67 (1.0%) 
Niacin 13 (0.4%) 9 (0.35%) 22 (0.3%) 
Antiplatelet therapy    
Any 3198 (97.9%) 3186 (98.2%) 6384 (98.0%) 
Aspirin 3063 (93.8%) 3063 (94.4%) 6126 (94.1%) 
Clopidrogel 2000 (61.3%) 1983 (61.1%) 3983 (61.2%) 
Other 40 (1.2%) 38 (1.2%) 78 (1.2%) 
Other cardiovascular therapy    
Beta-blocker 2141 (65.6%) 2160 (66.5%) 4301 (66.1%) 
Angiotensin-converting enzyme inhibitor or 
angiotensin receptor blocker 
1930 (59.1%) 1909 (58.8%) 3839 (59.0%) 
Calcium channel blocker 967 (29.6%) 938 (28.9%) 1905 (29.3%) 
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Nitrates 1191 (36.5%) 1217 (37.5%) 2408 (37.0%) 
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Table 2: Rates of Composite Cardiovascular Outcomes and Secondary Outcomes in Randomised Groups by Intention-to-Treat Analysis. 
Outcome Acarbose 
N=3272 
Placebo 
N=3250 
Hazard Ratio 
(95% CI) 
P 
Value 
 No. (%) No. per 100 
person-yrs. 
No. (%) No. per 100 
person-yrs. 
  
Primary cardiovascular outcome (5-point MACE) 470 (14.4) 3.33 479 (14.7) 3.4. 0.98 (0.86 to 1.11) 0.73 
Secondary outcomes       
Cardiovascular death, non-fatal myocardial 
infarction or non-fatal stroke (3-point MACE) 
285 (8.7) 1.93 299 (9.2) 2.04 0.95 (0.81 to 1.11) 0.51 
Death from any cause 216 (6.6) 1.42 219 (6.7) 1.45 0.98 (0.81 to 1.19) 0.85 
Cardiovascular death 145 (4.4) 0.96 163 (5.0) 1.03 0.89 (0.71 to 1.11) 0.23 
Fatal or non-fatal myocardial infarction 122 (3.7) 0.82 108 (3.3) 0.73 1.12 (0.87 to 1.46) 0.38 
Fatal or non-fatal stroke 75 (2.3) 0.50 77 (2.4) 0.52 0.97 (0.70 to 1.33) 0.83 
Hospitalisation for unstable angina 174 (5.3) 1.19 170 (5.2) 1.17 1.02 (0.82 to 1.26) 0.87 
Hospitalisation for heart failure 65 (2.0) 0.43 73 (2.2) 0.49 0.89 (0.63 to 1.24) 0.48 
Developed diabetes 436 (13.3) 3.17 513 (15.8) 3.84 0.82 (0.71 to 0.94)* 0.005 
Developed impaired kidney function
†
 41 (1.3) 0.33 50 (1.5) 0.41 0.81 (0.54 to 1.23)* 0.33 
*Rate ratios. † eGFR <30 ml/min/1.73m2, doubling of baseline serum creatinine level, or halving of baseline eGFR 
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Table 3: Adverse Events Reported During the Trial According to System Organ Class  
 
Acarbose 
(N=3263) 
Placebo 
(N=3241) 
 Patients Events Patients Events 
Serious adverse events*     
Neoplasms benign, malignant and unspecified  91 (2.8%) 109 
90 
(2.8%) 101 
Infections and infestations 79 (2.4%) 87 
77 
(2.4%) 86 
Gastrointestinal disorders  90 (2.8%) 94 
66 
(2.0%) 71 
Vascular disorders 49 (1.5%) 52 
37 
(1.1%) 43 
Nervous system disorders 39 (1.2%) 41 
26 
(0.8%) 62 
Musculoskeletal and connective tissue disorders 33 (1.0%) 34 
22 
(0.7%) 23 
Adverse events†     
Gastrointestinal disorders 250 (7.7%) 277 
179 
(5.5%) 187 
 
* Serious adverse events are reported where they occur in ≥1% of participants in either treatment group. 
† Adverse events associated with drug discontinuation or dose changes were reported where they occur in ≥5% in either treatment group. 
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Figure 1: 
 
 
1 Subjects were counted as completers if they had vital status assessed as alive or deceased at the trial termination visit and had not 
withdrawn consent. 
2 Subjects were counted as lost to follow-up if they were lost and their vital status could not be determined at the trial termination visit. 
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3 Time from randomization to the time of first primary composite outcome or the time when censored for first primary composite outcome 
according to the primary censoring scheme for event-free subjects, divided by the time from randomization to the time of first primary composite 
outcome or the expected follow-up time for event-free subjects as follows: vital status date at the trial termination visit for subjects counted as 
completers assessed as alive, the date of death for subjects counted as completers assessed as deceased, and the study cut-off date (1 Dec 
2016) for subjects who were counted as lost to follow-up or withdrew consent. 
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Figure 2: 
 
 
A B 
C D 
Rate ratio 0.82; 95% CI 
0.71 to 0.94 
